Home › Research › Treatments
A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease
Chundu UC, Thiriveedhi SR, Bhatti C, Mupparaju JS, Otinashvili N, Gelishvili E.. Cureus, 2025-06-04
Topic: Drug trials: efficacy and safety
Plain-language summary
Monoclonal antibody (mAb) therapies targeting amyloid-beta (Aβ) plaques have gained prominence over the past decade as potential disease-modifying treatments for Alzheimer's disease (AD), leading to major regulatory approvals and global debate. Nonetheless, the central question persists: does this emerging therapy have a justified role in the treatment protocol for AD? This systematic review evaluates the efficacy and safety of these agents across phase II and III clinical trials conducted in the past decade (2014-2024), aligning with the timeline when disease-modifying therapies gained momentum. A systematic search was performed across PubMed and the Cochrane Library to identify phase II and III randomized controlled trials (RCTs) conducted between January 2014 and December 2024. The inclusion criteria focused on studies that evaluated cognitive outcomes using scales such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and Mini-Mental State Examination (MMSE). Additionally, trials assessing biomarkers, including CSF measures and PET imaging, were included. Safety outcomes, particularly amyloid-related imaging abnormalities (ARIA), were also systematically analyzed. Due to heterogeneity in outcome measures, a narrative synthesis was conducted. Sixteen RCTs met the inclusion criteria. Lecanemab reduced amyloid burden with 81% of patients achieving amyloid-negative PET scans (Clarity AD trial) and showed a 27% reduction in cognitive decline on the ADCOMS scale. While statistically significant, the 27% ADCOMS (Alzheimer's Disease Composite Score) reduction warrants comparison to MCID (minimal clinically important difference) thresholds (e.g., ~0.5-1.0 points for CDR-SB in early AD) to assess real-world impact. Donanemab demonstrated 76% plaque clearance and a 35% slowing in cognitive decline in early AD patients. Aducanumab showed dose-dependent effects on plaque clearance but had inconsistent cognitive outcomes and higher ARIA rates. Recent mAb trials provide promising evidence for disease modification in early AD stages, particularly with lecanemab and donanemab. However, variability in cognitive outcomes and safety concerns warrant cautious interpretation and long-term validation.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Chundu, U. C., Thiriveedhi, SR., Bhatti, C., Mupparaju, J. S., Otinashvili, N., & Gelishvili, E. (2025). A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease. Cureus. https://doi.org/10.7759/cureus.85377
Vancouver
Chundu UC, Thiriveedhi SR, Bhatti C, Mupparaju JS, Otinashvili N, Gelishvili E. A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease. Cureus. 2025. doi:10.7759/cureus.85377. PMID: 40621323.
BibTeX
@article{chundu2025-40621323,
author = {Chundu, U. C. and Thiriveedhi, SR. and Bhatti, C. and Mupparaju, J. S. and Otinashvili, N. and Gelishvili, E.},
title = {{A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease}},
journal = {Cureus},
year = {2025},
doi = {10.7759/cureus.85377},
pmid = {40621323},
url = {https://doi.org/10.7759/cureus.85377}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- While statistically significant, the 27% ADCOMS (Alzheimer's Disease Composite Score) reduction warrants comparison to MCID (minimal clinically important difference) thresholds (e.g., ~0.5-1.0 points for CDR-SB in early AD) to assess real-world impact.
- Donanemab demonstrated 76% plaque clearance and a 35% slowing in cognitive decline in early AD patients.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 72/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 42 of the 58 points we could judge it on, which is 72 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Cureus) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40621323) |
| Free to read | 2 / 2 | Free to read |
| Points | 42 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 42 of the 58 points we could judge it on is 72 out of 100. |
| Total | 72 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.